CCM compared with IENF morphology in control subjects and diabetic patients stratified into different clinical severities of neuropathy according to NDS
| Control subjects | No neuropathy | Mild | Moderate | Severe | |
|---|---|---|---|---|---|
| CNFD (no/mm2)* | 43.20 ± 5.05 | 29.05 ± 3.07 | 22.95 ± 2.39§ | 22.59 ± 4.05§ | 20.13 ± 3.14§ |
| IENFD (no/mm)* | 11.21 ± 0.84 | 7.72 ± 1.28 | 5.56 ± 0.86§ | 5.84 ± 0.94§ | 2.54 ± 0.76§‖ |
| CNBD (no/mm2)* | 27.39 ± 3.31 | 8.10 ± 1.80† | 7.91 ± 1.70§ | 7.71 ± 2.24§ | 5.55 ± 2.19§ |
| IENFBD (no/mm2)† | 139.66 ± 23.42 | 57.55 ± 14.41 | 39.92 ± 10.53§ | 35.48 ± 10.81§ | 13.47 ± 5.79§ |
| CNFL (mm/mm2) | 6.14 ± 1.22 | 4.59 ± 0.92 | 3.87 ± 0.62 | 3.64 ± 0.56 | 3.69 ± 0.44 |
| IENFL (μm)‡ | 42.10 ± 4.31 | 38.00 ± 3.32 | 31.47 ± 2.46 | 29.59 ± 4.53 | 22.61 ± 7.12§ |
Data are means±SE in diabetic patients and control subjects. Statistically significant difference using ANOVA:
* P < 0.001;
† P < 0.01;
‡ P < 0.05.
§ Post hoc results significantly different from control subjects.
‖ Post hoc results significantly different from the group with no neuropathy.